Fig. 2From: Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysisComparing with initial value, there was a decline in CAS at 1 (a) and 3 (b) month after RTX treatment for TAOBack to article page